| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | XSTO Exchange | - ISIN |
| Sweden Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Dicot AB (publ) is a biopharmaceutical company with a focus on discovering and developing novel treatments for sexual dysfunction, headquartered in Uppsala, Sweden. Founded in 2015, the company has dedicated its efforts to addressing some of the most common yet challenging conditions affecting sexual health, including erectile dysfunction and premature ejaculation. With a strong commitment to improving patients' lives through innovative healthcare solutions, Dicot AB stands at the forefront of pharmaceutical research and development in Sweden.
As the flagship product under development by Dicot AB, LIB-01 is designed to tackle two prevalent sexual health issues: erectile dysfunction and premature ejaculation. This drug aims to provide a comprehensive solution that not only addresses the physiological aspects of these conditions but also the psychological factors that often accompany them. By focusing on the underlying causes of these conditions, LIB-01 represents a pioneering approach within the pharmaceutical industry, distinguishing Dicot AB as an innovator in the field of sexual health treatments.